Skip to main content
SpringerLink
Log in

Digestive Disease Week 2023 - Teil 3

Aktuelles von der DDW zur CED und Kolon

  • Aktuell
  • Published:
Gastro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© M. Gross

2
3
4

Literatur

  1. Feagan Bg et al. 1031 Upadacitinib Improves Endoscopic Outcomes In Patients With Moderate To Severely Active Crohn‘s Disease Irrespective Of Previous Failure To Respond To Biologics Or Conventional Therapies. Gastroenterology, 2023;164(6):223

  2. Peyrin-Biroulet L et al. Tu1723 Endoscopic And Clinical Outcomes Of Upadacitinib In Patients With Moderately To Severely Active Crohn‘s Disease By Number And Type Of Prior Biologics. Gastroenterology. 2023;164(6):1094-95

  3. Colombel Jf et al. Upadacitinib Therapy Reduces Crohn‘s Disease Symptoms Within The First Week Of Induction Therapy Gastroenterology. 2023;164(6):1091

  4. Lee Sd et al. 1027 Efficacy And Safety Of Intravenous Ustekinumab Reinduction Therapy In Crohn‘s Disease Patients With Secondary Loss Of Response To Ustekinumab Maintenance Therapy: Week 16 Results From The Power Trial. Gastroenterology. 2023;164(6):220-1

  5. Marin-Jimenez I et al. Analysis Of Baseline Characteristics Associated With Clinical Response To Ustekinumab Iv Re-Induction Strategy In Patients With Crohn's Disease In The Power Trial. Uegw 2023:Op188,

  6. Travis S et al.Vedolizumab For The Treatment Of Chronic Pouchitis. N Engl J Med. 2023;388(13):1191-200

  7. Outtier A et al. Ustekinumab As Induction And Maintenance Therapy For Chronic Antibiotic Refractory Pouchitis Gastroenterology. 2023;164(6):1089

  8. Panaccione R et al. Long-Term Efficacy And Safety Of Risankizumab Treatment In Patients With Moderately To Severely Active Crohn‘s Disease: 104-Week Results From The Fortify Study. Gastroenterology. 2023;164(6):1098

  9. Allegretti Jr et al. The Efficacy And Safety Of Guselkumab Induction Therapy In Patients With Moderately To Severely Active Ulcerative Colitis: Results From The Phase 3 Quasar Induction Study. Gastroenterology. 2023;164(6):1572

  10. Abreu Mt et al. Tu1725 Effects Of Ozanimod On Histologic Remission And Mucosal Healing Over 3 Years Of Continuous Treatment In Patients With Ulcerative Colitis. Gastroenterology. 2023;164(6):1096

  11. Sands Be et al. Tu1703 Gastroenterology. 2023;165(6):1084-5

  12. Vermeire S et al. Etrasimod For The Treatment Of Ulcerative Colitis: Up To 2.5 Years Of Pooled Safety Data From Global Clinical Trials. Gastroenterology. 2023;164(6):207

  13. Katibian Dj et al. Su1723 Withdrawal Of Immunomodulators In Patients With Inflammatory Bowel Disease In Remission On Combination Therapy: A Systematic Review And Meta-Analysis. Gastroenterology. 2023;164(6):652

  14. Pudipeddi A et al. 1029 Withdrawal Versus Continuation Of Thiopurine In Vedolizumab-Treated Patients With Ulcerative Colitis (Views): A Multi-Centre Randomised Controlled Trial. Gastroenterology. 2023;164(6):221

  15. Prentic R et al. 676 Phamracokinetics Of Vedolizumab And Ustekinumab In Pregnant Women With Inflammatory Bowel Disease And Their Infants Exposed In-Utero. Gastroenterology. 2023;164(6):133

  16. An Y-K et al. Mo1722 Reduction Of Bowel Wall Thickness And Doppler Signals As Eary As 36 Hours Predicts Corticosteroid Response In A Multi-Centre Prospective Cohort Of Acute Severe Ulcerative Colitis: Usuc Study Including Genius Cohort Gastroenterology. 2023;164(6):879

  17. Jenkinson P et al. Mo1782. Gastroenterology. 2023;164(6):908

  18. Wang Y et al. Randomized Clinical Trial Of Infliximab Versus Vedolizumab For Immune Checkpoint Inhibitor Related Colitis. Gastroenterology. 2023;164(6):1101

  19. Thomas As et al. Il12/23 Blockade For Refractory Immune-Mediated Colitis: 2-Center Experience. Am J Gastroenterol. 2023;118(9):1679-83

  20. Feuerstadt P et al. Ser-109, An Oral Microbiome Therapy For Recurrent Clostridioides Difficile Infection. N Engl J Med. 2022;386:220-9

  21. Huang Es et al. Durability Of The Clinical Response To Ser-109, An Investigational Oral Microbiome Therapeutic, In A Phase 3 Open-Label Trial (Ecospor Iv) In Patients With Recurrent Clostridioides Difficile Infection. Gastroenterology.2023;164(6):141

  22. Dubberke Er et al. Safety And Efficacy Of Rbx2660 In Reducing Recurrent Clostridioides Difficile Infection In Immunocompromised Participants. Gastroenterology. 2023;164(6):143-4

  23. Menon R et al. Pharmacodynamic Response To A Defined Bacterial Consortium, Ve303, In Patients With Clostridioides Difficile Infection (Cdi): Results Of The Phase 2 Consortium Study. Gastroenterology. 2023;164(6):141

Download references

Author information

Authors and Affiliations

  1. Klinik für Allgemeine Innere Medizin und Gastroenterologie, Internistisches Klinikum München Süd, Am Isarkanal 36, 81379, München, Germany

    Manfred Gross (Chefarzt und Ärztlicher Direktor)

Authors
  1. Manfred Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred Gross.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gross, M. Aktuelles von der DDW zur CED und Kolon. Gastro-News 10, 62–66 (2023). https://doi.org/10.1007/s15036-023-3344-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15036-023-3344-6

Search

Navigation